Loading news...
Zealand Pharma A/S (ZLDPF) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Zealand Pharma obesity drug showed disappointing weight loss in a Phase 2 trial.
The company said the data supported further development of the drug in chronic weight management on its own or in combination with other drugs due to its tolerability.
Zealand Pharma A/S (ZLDPF) Discusses Top Line Phase II Results for ZUPREME-1 Trial of Petrelintide in Obesity Transcript
Zealand Pharma A/S (ZLDPF) Q4 2025 Earnings Call Transcript
Zealand Pharma AS (ZLDPF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zealand Pharma A/S (ZLDPF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Zealand Pharma A/S (ZLDPF) Analyst/Investor Day Transcript
Danish biotech Zealand Pharma said on Thursday it will accelerate development and expand its research as it seeks to differentiate its experimental obesity drug candidates in an increasingly competitive race to treat metabolic health issues.
Zealand Pharma A/S (OTCPK:ZLDPF) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Adam Steensberg - President & CEO David Kendall - Executive VP, Chief Medical Officer & Head of R&D Henriette Wennicke - EVP & CFO Conference Call Participants Kirsty Ross-Stewart - BNP Paribas, Research Division Hakon Hemme Jørgensen - Danske Bank A/S, Research Division Lucy-Emma Codrington-Bartlett - Jefferies LLC, Research Division Tsan-Yu Hsieh - William Blair & Company L.L.C., Research Division Kerry Holford - Joh.
Zealand Pharma is halting development of a potential next-generation obesity drug after concluding the market has become too crowded for it to stand out, Bloomberg News reported on Thursday, citing an interview with the company CEO.
Zealand Pharma A/S (OTCPK:ZLDPF) Bank of America Global Healthcare Conference 2025 September 25, 2025 5:45 AM EDT Company Participants David Kendall - Executive VP, Chief Medical Officer & Head of R&D Conference Call Participants Charlie Haywood - BofA Securities, Research Division Benjamin Yeoh Presentation Charlie Haywood BofA Securities, Research Division I think we'll get going if that works for everyone. I'm Charlie Haywood from the BofA EU Pharma team.
Zealand Pharma is considering a direct-to-patient sales model for its experimental weight-loss drug alongside traditional insurer channels, its CEO told Reuters in an interview on Monday, citing shifting dynamics in the booming obesity drug market.
Zealand Pharma A/S (OTCPK:ZLDPF) Cantor Global Healthcare Conference 2025 September 4, 2025 8:00 AM EDT Company Participants Adam Steensberg - President & CEO Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Presentation Prakhar Agrawal Senior Biotech Analyst All right. Good morning, everyone.
Zealand Pharma A/S (OTCPK:ZLDPF) Q2 2025 Earnings Call August 14, 2025 8:00 AM ET Company Participants Adam Langer - Corporate Participant Adam Sinding Steensberg - President & CEO David M. Kendall - Executive VP, Chief Medical Officer & Head of R&D Henriette Wennicke - EVP & CFO Conference Call Participants Benjamin Jackson - Jefferies LLC, Research Division Carsten Lønborg Madsen - Danske Bank A/S, Research Division Jacob Mekhael - KBC Securities NV, Research Division Kirsty Ross-Stewart - BNP Paribas Exane, Research Division Michael Novod - Nordea Markets, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Rajan Sharma - Goldman Sachs Group, Inc., Research Division Rei Tan - BTIG, LLC, Research Division Sophia Graeff Buhl Nielsen - JPMorgan Chase & Co, Research Division Tsan-Yu Hsieh - William Blair & Company L.L.C.
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
Zealand Pharma said its obesity treatment dapiglutide showed positive topline results in its latest trial, demonstrating its further potential for weight loss and to treat obesity-related comorbidities.
Zealand Pharma A/S (OTCPK:ZLDPF) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Adam Lange - Vice President, Investor Relations Adam Steensberg - President & Chief Executive Officer David Kendall - Chief Medical Officer Henriette Wennicke - Chief Financial Officer Eric Cox - Chief Commercial Officer Conference Call Participants Michael Novod - Nordea Andy Hsieh - William Blair Prakhar Agrawal - Cantor Fitzgerald Chiara Montironi - Van Lanschot Kempen Charlie Haywood - Bank of America Shan Hama - Jefferies Ollie Burrow - Goldman Sachs Adam Lange Thank you to everyone for joining us today to discuss Zealand Pharma's results for the First Three Months of 2025. You can find the related company announcements on our website at zealandpharma.com.
Roche and Zealand Pharma in March struck a deal worth up to $5.3 billion to co-develop and co-commercialize amylin analog petrelintide as a potentially "next generation" weight loss drug. Executives at both firms told CNBC a "very competitive process" left both firms hashing out the details until the eleventh hour.
Zealand Pharma AS (ZLDPF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.